How is it different from interferon alfa or beta?

Interferon gamma is a type II interferon that mainly boosts phagocyte antimicrobial activity, whereas alfa and beta are type I interferons used chiefly for antiviral, antitumor, or multiple-sclerosis indications. Gamma-1b also does not carry the interferon-alpha boxed warning.

What evidence supports its use in CGD?

A landmark 1991 placebo-controlled randomized trial by the International CGD Cooperative Study Group showed it significantly reduced serious infections. Long-term follow-up studies later confirmed sustained benefit.

What are the common side effects?

Flu-like symptoms such as fever, chills, headache, muscle aches, and fatigue are the most common, especially when starting treatment. Injection-site reactions, transient neutropenia, and liver-enzyme elevations can also occur.

Is it a supplement or something I can take for general immunity?

No. It is a prescription injectable biologic approved only for specific rare diseases and must be prescribed and monitored by a physician. It is not a general immune booster or wellness product.

EMA-approvedaka Actimmune

Interferon gamma-1b — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Interferon gamma-1b (also known as Actimmune) is a peptide catalogued under Immune (IFN-γ). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Interferon gamma-1b?

Interferon gamma-1b (brand name Actimmune) is a recombinant form of human interferon-gamma, a type II interferon produced in E. coli. It is an FDA-approved prescription biologic indicated to reduce the frequency and severity of serious infections in chronic granulomatous disease (CGD) and to delay disease progression in severe, malignant osteopetrosis.

Its CGD approval rests on a landmark placebo-controlled randomized trial, and its use is supported by human clinical-trial and long-term follow-up evidence. It is distinct from the interferon-alpha and interferon-beta products and does not share their boxed warning, though it is still a specialist-managed drug.

How does Interferon gamma-1b work?

Interferon gamma-1b binds the interferon-gamma receptor and activates JAK-STAT signaling, principally enhancing phagocyte (macrophage and neutrophil) oxidative metabolism and antimicrobial killing.

In CGD it augments the residual respiratory-burst and immune activity, reducing susceptibility to serious infections.

What does the research say about Interferon gamma-1b?

Reduces the frequency of serious infections in chronic granulomatous disease, demonstrated in the pivotal placebo-controlled randomized trial that supported FDA approval. ^[1]
Sustains reduced infection rates over years of continued therapy in chronic granulomatous disease during long-term follow-up. ^[2]
Improves bone remodeling and disease course in severe malignant osteopetrosis with long-term recombinant interferon-gamma treatment. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease — International Chronic Granulomatous Disease Cooperative Study Group, New England Journal of Medicine 1991. (Randomized controlled trial)
[2] Long-term interferon-gamma therapy for patients with chronic granulomatous disease — Marciano BE et al., Clinical Infectious Diseases 2004. (Clinical trial / long-term follow-up)
[3] Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease — Todd PA et al., Drugs 1992. (Review)
[4] Long-term treatment of osteopetrosis with recombinant human interferon gamma — Key LL Jr et al., New England Journal of Medicine 1995. (Clinical trial)
[5] Recombinant human interferon gamma therapy for osteopetrosis — Key LL Jr et al., Journal of Pediatrics 1992. (Clinical trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use it is given by subcutaneous injection three times weekly, with the dose calculated from body-surface area and managed by a specialist.

This is contextual background only, not a dosing recommendation, and any use requires physician supervision and monitoring.

Side effects & safety profile

Interferon gamma-1b commonly causes a flu-like syndrome (fever, chills, headache, myalgia, fatigue), particularly at the start of therapy, and injection-site reactions.

It can also cause reversible neutropenia and elevated liver enzymes, and caution is advised in patients with cardiac disease, seizure disorders, or myelosuppression; it does not carry the interferon-alpha class boxed warning.

As a prescription injectable it requires physician monitoring and is not a wellness or performance compound.

Stacking & combinations

In CGD it is generally used alongside standard antibacterial and antifungal prophylaxis as part of an infection-prevention regimen, under specialist care rather than as an unsupervised combination.

Finding Interferon gamma-1b vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA-approved as Actimmune to reduce the frequency and severity of serious infections in chronic granulomatous disease (CGD) and to delay time to disease progression in severe, malignant osteopetrosis. Both are rare conditions managed by specialists.

References

[1] A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease — International Chronic Granulomatous Disease Cooperative Study Group, New England Journal of Medicine 1991. PMID: 1846940. View sourceStudy: Randomized controlled trialInterferon gamma significantly reduced the number of serious infections in patients with chronic granulomatous disease versus placebo.
[2] Long-term interferon-gamma therapy for patients with chronic granulomatous disease — Marciano BE et al., Clinical Infectious Diseases 2004. PMID: 15356785. View sourceStudy: Clinical trial / long-term follow-upLong-term interferon-gamma therapy was associated with sustained reduction in serious infections and was generally well tolerated in CGD.
[3] Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease — Todd PA et al., Drugs 1992. PMID: 1372855. View sourceStudy: ReviewReviewed the pharmacology and clinical efficacy of interferon gamma-1b in reducing infections in chronic granulomatous disease.
[4] Long-term treatment of osteopetrosis with recombinant human interferon gamma — Key LL Jr et al., New England Journal of Medicine 1995. PMID: 7753137. View sourceStudy: Clinical trialLong-term recombinant interferon-gamma improved bone resorption, hematologic status, and infection resistance in severe osteopetrosis.
[5] Recombinant human interferon gamma therapy for osteopetrosis — Key LL Jr et al., Journal of Pediatrics 1992. PMID: 1320672. View sourceStudy: Clinical trialRecombinant interferon-gamma enhanced osteoclast superoxide production and bone resorption in children with osteopetrosis.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.